Repligen price target raised to $207 from $165 at Stifel

Stifel analyst Daniel Arias raised the firm’s price target on Repligen to $207 from $165 and keeps a Buy rating on the shares. While below consensus, top-line FY24 guidance was “solid” when taking account the headwinds that are expected in Proteins this year, the analyst tells investors. Near-term upside may be limited, but the business should be on its way back, which should keep investors interested and engaged on a 12-month basis, the firm adds.